Stay updated on Nivolumab Radiotherapy Combo in Advanced Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Radiotherapy Combo in Advanced Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Radiotherapy Combo in Advanced Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:42:46.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a potential update in the overall survival rate at 1 year when combining nivolumab with multisite, multifractionated high dose radiotherapy in advanced melanoma patients without prior antitumoral treatment.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:12.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health condition, and prior treatments, particularly for those with Stage III or IV melanoma. Previously, this section had no information provided.
    Difference
    32%
    Check dated 2024-05-22T20:56:40.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:28:41.000Z thumbnail image

Stay in the know with updates to Nivolumab Radiotherapy Combo in Advanced Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Radiotherapy Combo in Advanced Melanoma Clinical Trial page.